Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 921,942	$ 990,457
Accounts receivable, net of allowance of $2,500	102,310	94,413
Inventories	56,805	53,973
Prepaid expenses and other current assets	32,745	20,000
Total current assets	1,113,802	1,158,843
Equipment, net of depreciation	117,295	108,865
Other non-current assets	32,530	32,530
Deferred offering cost	191,494	195,182
Total assets	1,455,121	1,495,420
Current liabilities:
Accounts payable and accrued expenses	351,000	224,105
Convertible notes payable	5,398,847	5,248,847
Discount on convertible notes payable, net of amortization	(697,231)	(1,257,182)
Total current liabilities	5,052,616	4,215,770
Long-term liabilities:
Line of credit	390,000
Convertible notes payable	1,769,271	1,539,271
Discount on convertible notes payable and line of credit, net of amortization	(1,141,478)	(850,000)
Total liabilities	6,070,409	4,905,041
COMMITMENTS, CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY (DEFICIT):
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -no Shares Issued and Outstanding, at December 31, 2017 and March 31, 2018
Common stock, $.00067 Par Value, 200,000,000 Shares Authorized, 104,164,465 and 106,406,584 Shares Issued, at December 31, 2017 and March 31, 2018	71,421	69,871
Additional paid-in capital	98,605,285	97,093,144
Accumulated deficit	(103,825,209)	(101,204,846)
Accumulated other comprehensive loss	(54,840)	(62,489)
Total Biolargo, Inc. and Subsidiaries stockholders’ equity (deficit)	(5,203,343)	(4,104,320)
Non-controlling interest (Note 9)	588,055	694,699
Total stockholders’ equity (deficit)	(4,615,288)	(3,409,621)
Total liabilities and stockholders’ equity (deficit)	$ 1,455,121	$ 1,495,420